Literature DB >> 31066039

LncRNAs associated with multiple sclerosis expressed in the Th1 cell lineage.

Aref Hosseini1, Shohreh Teimuri2, Marzieh Ehsani1, Seyed Mohammad Mahdi Rasa1, Masoud Etemadifar3, Mohammad Hossein Nasr Esfahani2, Timothy L Megraw4, Kamran Ghaedi1,2.   

Abstract

Multiple sclerosis (MS) is a type of inflammatory and demyelinating disorder of the central nervous system in which immune-mediated inflammatory processes are elicited by secreted cytokines from T helper (Th)-1 and Th17 cells. While some protein-coding genes expressed in T cell types have established involvement in MS disease progression, little is understood about the roles of long noncoding RNAs (lncRNAs) within the disease landscape. LncRNAs, noncoding RNAs longer than 200 nucleotides, likely control gene expression and function of Th1 cells, and offer the potential to act as therapeutic and biomarker candidates for MS. We identified lncRNAs in Th1 cells linked to MS. Expression levels of candidate lncRNAs and genes were evaluated in 50 MS patients and 25 healthy controls using quantitative real-time polymerase chain reaction, and their correlations were assessed. LncRNAs encoded by AC007278.2 and IFNG-AS1-001 showed significantly higher expression in relapsing Phase MS patients whereas IFNG-AS1-003 was elevated in patients in the remitting phase compared with relapsing patients. Collectively, these misregulated lncRNAs may provide valuable tools to understand the relationships between lncRNAs and MS, and possibly other related disorders.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CNS; T helper 1; biomarker; lncRNA; multiple sclerosis

Mesh:

Substances:

Year:  2019        PMID: 31066039     DOI: 10.1002/jcp.28779

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Potential Biomarker and Therapeutic LncRNAs in Multiple Sclerosis Through Targeting Memory B Cells.

Authors:  Elahe Ghoveud; Shohreh Teimuri; Jafar Vatandoost; Aref Hosseini; Kamran Ghaedi; Masood Etemadifar; Mohammad Hossein Nasr Esfahani; Timothy L Megraw
Journal:  Neuromolecular Med       Date:  2019-10-01       Impact factor: 3.843

2.  Dysregulation of long noncoding RNA MEG3 and NLRC5 expressions in patients with relapsing-remitting multiple sclerosis: is there any correlation?

Authors:  Shahram Torkamandi; Shima Bahrami; Tahereh Ghorashi; Mohammad Dehani; Hadi Bayat; Seyyed Mohamad Hoseini; Somaye Rezaei; Mohsen Soosanabadi
Journal:  Genes Immun       Date:  2021-11-15       Impact factor: 2.676

Review 3.  LncRNAs in adaptive immunity: role in physiological and pathological conditions.

Authors:  Pedro Faria Zeni; Marek Mraz
Journal:  RNA Biol       Date:  2020-11-09       Impact factor: 4.652

Review 4.  What do we know about the role of lncRNAs in multiple sclerosis?

Authors:  Viviana Nociti; Massimo Santoro
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

5.  Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.

Authors:  Aya A Elkhodiry; Hend M El Tayebi
Journal:  Noncoding RNA Res       Date:  2021-12-07

Review 6.  Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases.

Authors:  Valeria Lodde; Giampaolo Murgia; Elena Rita Simula; Maristella Steri; Matteo Floris; Maria Laura Idda
Journal:  Biomolecules       Date:  2020-07-14

7.  Uncovering Potential lncRNAs and mRNAs in the Progression From Acute Myocardial Infarction to Myocardial Fibrosis to Heart Failure.

Authors:  Shuo Wang; Enmao Wang; Qincong Chen; Yan Yang; Lei Xu; Xiaolei Zhang; Rubing Wu; Xitian Hu; Zhihong Wu
Journal:  Front Cardiovasc Med       Date:  2021-07-16

Review 8.  Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review.

Authors:  Abbas Jalaiei; Mohammad Reza Asadi; Hani Sabaie; Hossein Dehghani; Jalal Gharesouran; Bashdar Mahmud Hussen; Mohammad Taheri; Soudeh Ghafouri-Fard; Maryam Rezazadeh
Journal:  Front Immunol       Date:  2021-12-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.